Table 2. Investigated areas of improvement of docetaxel-based chemotherapy.

Area of improvement	Outcome
Weekly schedules	Alternative for patients at high risk for myelotoxic complications
PK	Interindividual variability can be decreased by phenotypic individualised dosing
	Most predictive phenotyping probe controversial
	Practical disadvantages of phenotyping in oncology practice
	TDM requires investigation
Reversal of resistance	ABCB1-modulating agents insufficiently reverse (multi)drug resistance due to multiple resistance mechanisms
Oral administration	Oral administration feasible upon pharmacologic modulation
	Second-generation oral taxanes likely to prevail
Second-generation taxanes	In clinical phase I/II development; also oral drugs
Alternative formulations	Alternative formulations in preclinical phase
	Introduction not foreseen in near future
Pharmacogenomics and pharmacogenetics	Sufficiently powered trials necessary to determine clinical relevance

PK=pharmacokinetics; TDM=therapeutic drug monitoring.